HT
FATE icon

Headlands Technologies’s Fate Therapeutics FATE Stock Holding History

Headlands Technologies’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$151K Buy
+125,708
New +$153K 0.02% 633
2025
Q3 		– Sell
-49,556
Closed -$55.5K – 841
2025
Q2 		$55.5K Buy
+49,556
New +$57.6K 0.01% 756
2024
Q3 		– Sell
-28,508
Closed -$93.5K – 1294
2024
Q2 		$93.5K Buy
28,508
+27,976
+5,259% +$122K 0.01% 659
2024
Q1 		$3.9K Buy
+532
New +$3.29K ﹤0.01% 1121

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Headlands Technologies's FATE Position: Q1 2026 in Review

Headlands Technologies opened a new position in Fate Therapeutics (FATE) in Q1 2026: 125,708 shares worth $151K. The stake represents 0.02% of the portfolio and ranks #633 among its holdings. This is a return to the name: Headlands Technologies previously reported a position in FATE as recently as Q2 2025.

Headlands Technologies first reported a position in FATE in Q1 2024 and has held it in 4 quarters since. 157 funds tracked by Wall St. Rank hold FATE as of Q1 2026.

  • Headlands Technologies held 125,708 shares of Fate Therapeutics worth $151K as of Q1 2026.
  • Fate Therapeutics was a new Headlands Technologies position in Q1 2026.
  • Fate Therapeutics made up 0.02% of Headlands Technologies's portfolio in Q1 2026, its #633 holding.
  • Headlands Technologies first reported a position in Fate Therapeutics in Q1 2024 and has held it in 4 quarters since.
  • 157 funds tracked by Wall St. Rank held Fate Therapeutics as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.